AdvaMed Answers Scully On Cost Effectiveness Role In Medicare Coverage
This article was originally published in The Gray Sheet
Executive Summary
AdvaMed maintains that CMS consideration of cost-effectiveness would bias Medicare coverage decisions against technologies early in a product's lifecycle
You may also be interested in...
Scully’s Successor Awaited By Device Reps: Will Improved Access Continue?
Retaining access to top-level CMS officials is a primary objective of device stakeholders following the imminent departure of Administrator Tom Scully
Scully’s Successor Awaited By Device Reps: Will Improved Access Continue?
Retaining access to top-level CMS officials is a primary objective of device stakeholders following the imminent departure of Administrator Tom Scully
Tunis Presses NIH To Share ICD Study Findings; Dollens Claims Data Irrelevant
CMS will contact the National Heart, Lung & Blood Institute within the next two weeks to try to determine why SCD-HeFT study patients who met the MADIT-II trial criteria were not switched to the active ICD treatment arm